A novel GLP-1/GIP dual agonist is more effective than liraglutide in reducing inflammation and enhancing GDNF release in the MPTP mouse model of Parkinson's disease.
A novel GLP-1/GIP Dualagonist is more effective than liraglutide in reducing inflammation and strengthening GDNF in the MPTP mouse model of Parkinson's disease.